Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Submits Aries System, Herpes Assay for FDA Clearance

NEW YORK (GenomeWeb) – Luminex today announced that it has submitted 510(k) applications to the US Food and Drug Administration for the firm's Aries platform and HSV 1&2 Assay.

Aries is a cartridge-based, sample-to-answer system that uses real-time PCR for detection and quantification of nucleic acid targets. It offers higher throughput than the firm's earlier-generation xTag platform, but does not offer the same degree of multiplexing. The Aries platform also includes a built-in touchscreen computer.

"In Aries, we believe we have a truly differentiated product that will resonate quite favorably with laboratory customers," Luminex CEO Homi Shamir said in a statement. "As we near the commercial launch of the system, scheduled for later this year, we are excited to enter the next phase of the company's future, with an ever-increasing focus on the molecular diagnostics market, rapidly expanding the Aries menu and driving top-line revenue growth." 

Luminex said it anticipates receiving FDA clearance and CE-IVD marking by the end of the year. Clinical trials for Aries Clostridium difficile and Group B Streptococcus assays are in progress and the firm expects to launch trials for more assays by the end of the year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.